| Literature DB >> 15365572 |
K Fukuda1, C Sakakura, K Miyagawa, Y Kuriu, S Kin, Y Nakase, A Hagiwara, S Mitsufuji, Y Okazaki, Y Hayashizaki, H Yamagishi.
Abstract
Radiation therapy is a powerful tool for the treatment of oesophageal cancer. We established radioresistant cell lines by applying fractionated irradiation in order to identify differentially expressed genes between parent and radioresistant cells. Six oesophageal cancer cell lines (TE-2, TE-5, TE-9, TE-13, KYSE170, and KYSE180) were treated with continuous 2 Gy fractionated irradiation (total dose 60 Gy). We compared expression profiles of each parent and radioresistant lines on a cDNA microarray consisting of 21168 genes. In the fractionated irradiation trial, four radioresistant sublines (TE-2R, TE-9R, TE-13R, KYSE170R) were established successfully, and we identified 19 upregulated and 28 downregulated genes common to radioresistant sublines. Upregulated genes were associated with apoptosis and inflammatory response (BIRC2 and COX-2), DNA metabolism (CD73), and cell growth (PLAU). Downregulated genes were associated with apoptosis (CASP6), cell adhesion (CDH1 and CDH3), transcription (MLL3), and cell cycle (CDK6). Some of these genes were known to be associated with radiation response, such as COX-2, but others were novel. Reverse transcription-polymerase chain reaction confirmed that genes selected by cDNA microarray were overexpressed in clinical specimens of radioresistant cases. Global gene analysis of radioresistant sublines may provide new insight into mechanisms of radioresistance and effective radiation therapy.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15365572 PMCID: PMC2409931 DOI: 10.1038/sj.bjc.6602187
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Clonogenic survival parameters fitting the data to a multitarget model
| TE-2 | ||||
| Control | 0.75 | [0.68–0.84] | 2.63 | [1.49–4.63] |
| Resistant | 1.05 | [0.95–1.19] | 2.85 | [1.57–5.15] |
| TE-5 | ||||
| Control | 0.69 | [0.57–0.85] | 13.97 | [4.05–48.24] |
| Resistant | 0.73 | [0.65–0.85] | 9.25 | [4.21–20.29] |
| TE-9 | ||||
| Control | 1.14 | [1.00–1.32] | 1.76 | [1.21–2.55] |
| Resistant | 1.71 | [1.53–1.93] | 1.60 | [1.15–2.23] |
| TE-13 | ||||
| Control | 1.49 | [1.39–1.61] | 2.42 | [1.76–3.34] |
| Resistant | 1.83 | [1.70–1.98] | 2.61 | [1.97–3.45] |
| KYSE170 | ||||
| Control | 1.31 | [1.17–1.49] | 2.46 | [1.55–3.90] |
| Resistant | 1.76 | [1.49–2.17] | 2.73 | [1.38–5.37] |
| KYSE180 | ||||
| Control | 0.91 | [0.84–0.99] | 2.43 | [1.74–3.38] |
| Resistant | 0.97 | [0.89–1.07] | 2.02 | [1.43–2.84] |
D0 was used as a parameter to indicate the amount of irradiation required to reduce the survival fraction to approximately 0.37 from the survival curve.
Cell cycle distributions of the cell lines
| TE-2 | |||
| Control | 54.9 | 18.1 | 27 |
| Resistant | 49 | 22.5 | 28.5 |
| TE-9 | |||
| Control | 57.3 | 16.1 | 26.6 |
| Resistant | 60.8 | 17.2 | 21.9 |
| TE-13 | |||
| Control | 49.5 | 23.9 | 26.6 |
| Resistant | 53.1 | 24.7 | 22.2 |
| KYSE-170 | |||
| Control | 51.8 | 17 | 31.2 |
| Resistant | 56 | 16.7 | 27.3 |
Upregulated genes in radioresistant sublines in comparison to parent cell lines
| Apoptosis, inflammatory response | AA418021 | ICEBERG caspase-1 inhibitor (ICEBERG) | 2.18 | 1.04 | 4.18 | 2.06 |
| Apoptosis | R44417 | baculoviral IAP repeat-containing 2 (BIRC2) | 2.23 | 2.28 | 1.57 | 2.96 |
| Blood coagulation, cell growth | AA284669 | plasminogen activator, urokinase (PLAU) | 2.64 | 2.48 | 1.11 | 3.23 |
| Carbohydrate metabolism | AA775378 | mannosyl (alpha-1,3-)-glycoprotein beta-1,2- | 2.06 | 8.18 | 0.45 | 3.06 |
| Cell adhesion, immune response | AA458965 | natural killer cell transcript 4 (NK4) | 7.03 | 8.53 | 1.03 | 2.28 |
| DNA metabolism | R60343 | 5′ nucleotidase (CD73) (NT5) | 2.21 | 0.54 | 4.45 | 4.26 |
| Electron transport | AA418907 | cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 (CYP1A1) | 7.19 | 2.19 | 0.41 | 2.67 |
| Electron transport | R33030 | glucose regulated protein, 58 kDa (GRP58) | 2.80 | 2.11 | 1.51 | 3.22 |
| Electron transport | AA430497 | protein disulphide isomerase related protein (calcium-binding protein, intestinal-related) (ERP70) | 9.78 | 2.92 | 1.11 | 2.94 |
| Inflammatory response | R80217 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2) (COX-2) | 2.16 | 3.17 | 4.16 | 1.29 |
| Protein amino-acid phosphorylation | AA447574 | protein kinase C, zeta (PRKCZ) | 2.00 | 10.04 | 0.92 | 3.70 |
| Protein amino-acid phosphorylation | N94921 | receptor tyrosine kinase-like orphan receptor 2 (ROR2) | 2.05 | 0.95 | 5.06 | 2.30 |
| Protein amino-acid phosphorylation | H74007 | serum/glucocorticoid regulated kinase (SGK) | 4.04 | 2.20 | 2.51 | 1.00 |
| Regulation of transcription, DNA-dependent | AA293192 | putative nucleic acid binding protein RY-1 (RY1) | 2.17 | 2.32 | 1.00 | 2.37 |
| Transport | AA400973 | lipocalin 2 (oncogene 24p3) (LCN2) | 3.01 | 2.33 | 1.31 | 5.47 |
| tRNA processing | AA156571 | alanyl-tRNA synthetase (AARS) | 3.81 | 2.29 | 0.66 | 2.39 |
| Unclassified | T67069 | GTP binding protein 2 (GTPBP2) | 2.77 | 2.42 | 1.10 | 2.96 |
| Unclassified | N90081 | tripartite motif protein TRIM8 (TRIM8) | 2.28 | 2.35 | 0.99 | 6.68 |
| Unclassified | AA453410 | tumour necrosis factor receptor superfamily, member 10b (TNFRSF10B) | 2.08 | 19.12 | 0.92 | 3.03 |
Representative functions of the genes as previously reported, accession number, gene name, and fold change of each radioresistant subline compared to their parent cell line are shown. Only the genes that showed more than two-fold change in at least three of the four radioresistant sublines are sorted by cDNA microarray data.
Downregulated genes in radioresistant sublines in comparison to parent cell lines
| Apoptosis | W45688 | caspase 6, apoptosis-related cysteine protease (CASP6) | 0.09 | 0.14 | 0.04 | 0.04 |
| Carbohydrate metabolism | AA193116 | glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1) | 1.64 | 0.37 | 0.44 | 0.37 |
| Cell adhesion | H97778 | cadherin 1, type 1, E-cadherin (epithelial) (CDH1) | 0.05 | 0.25 | 0.07 | 0.02 |
| Cell adhesion | AA425217 | cadherin 3, type 1, P-cadherin (placental) (CDH3) | 0.05 | 0.22 | 0.03 | 0.02 |
| Cell adhesion | N63057 | protocadherin 9 (PCDH9) | 0.43 | 0.07 | 0.69 | 0.36 |
| Cell growth, cell–cell signalling | W56771 | endometrial bleeding associated factor (left–right determination, factor A; transforming growth factor beta superfamily) (EBAF) | 0.45 | 1.00 | 0.19 | 0.40 |
| Epidermal differentiation | W23757 | keratin 13 (KRT13) | 0.37 | 0.30 | 3.32 | 0.19 |
| Intracellular protein transport | R28020 | RAB2, member RAS oncogene family (RAB2) | 0.07 | 0.20 | 0.03 | 0.03 |
| Intracellular signalling cascade | R91570 | signal transducer and activator of transcription 4 (STAT4) | 0.19 | 0.12 | 0.09 | 0.06 |
| Ion transport | T52201 | chloride intracellular channel 2 (CLIC2) | 0.60 | 0.40 | 0.48 | 0.32 |
| Metabolism | AA668821 | chitinase 3-like 2 (CHI3L2) | 0.42 | 0.45 | 0.61 | 0.15 |
| Mitosis, regulation of CDK activity | AA608568 | cyclin A2 (CCNA2) | 0.36 | 0.42 | 0.44 | 2.90 |
| Neurogenesis | AA425008 | cerebellin 1 precursor (CBLN1) | 1.09 | 0.37 | 0.20 | 0.21 |
| Oncogenesis | W69960 | Wolf–Hirschhorn syndrome candidate 1 (WHSC1) | 0.12 | 0.10 | 0.05 | 0.10 |
| Protein amino-acid phosphorylation | AA598841 | natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) (NPR1) | 0.46 | 0.34 | 0.74 | 0.41 |
| Proteolysis and peptidolysis | H94487 | cathepsin E (CTSE) | 0.79 | 0.39 | 0.34 | 0.12 |
| Regulation of cell cycle | H73724 | cyclin-dependent kinase 6 (CDK6) | 0.27 | 0.53 | 0.15 | 0.10 |
| Regulation of transcription, DNA dependent | H82435 | myeloid/lymphoid or mixed-lineage leukaemia 3 (MLL3) | 0.29 | 0.46 | 0.39 | 0.56 |
| Regulation of transcription, DNA dependent | AA480906 | protein kinase C binding protein 1 (PRKCBP1) | 0.40 | 0.23 | 1.10 | 0.48 |
| Signal transduction | H93332 | apolipoprotein B (including Ag(x) antigen) (APOB) | 0.37 | 0.49 | 0.56 | 0.46 |
| Skeketal development | W58032 | frizzled-related protein (FRZB) | 0.67 | 0.45 | 0.43 | 0.35 |
| Steroid metabolism | N92404 | sulphotransferase, oestrogen-preferring (STE) | 1.00 | 0.28 | 0.18 | 0.30 |
| Unclassified | AA454819 | mitogen-activated protein kinase 3 (MAPK3) | 0.21 | 0.29 | 0.07 | 0.11 |
| Unclassified | AA450024 | T-cell lymphoma invasion and metastasis 2 (TIAM2) | 0.16 | 0.17 | 0.04 | 0.07 |
| Unclassified | R89492 | cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9 (CYP2C9) | 0.49 | 0.50 | 0.55 | 0.29 |
| Unclassified | AA487505 | immunoglobulin superfamily, member 4 (IGSF4) | 0.39 | 0.28 | 0.55 | 0.44 |
| Unclassified | AA490903 | pleckstrin homology, Sec7 and coiled/coil domains, binding protein (PSCDBP) | 0.43 | 0.40 | 0.83 | 0.49 |
| Unclassified | AA417616 | B-cell CLL/lymphoma 7A (BCL7A) | 0.35 | 0.22 | 0.13 | 0.09 |
Representative functions of the genes as previously reported, accession number, gene name, and fold change of each radioresistant subline compared to their parent cell line are shown. Only the genes that showed more than two-fold change in at least three of the four radioresistant sublines are sorted by cDNA microarray data.
Figure 1Quantitative RT–PCR analysis of the genes selected for cDNA microarray data validation. (A) Relative expression rate of COX-2 was normalised to beta-actin. (B) Relative expression rate of BIRC2 was normalised to beta-actin. Data represent mean±standard deviation (n=3).
Figure 2Effect of radiotherapy and expression rate of COX-2 (A) and BIRC2 (B) in clinical specimens. Expression rates were normalised to beta-actin. The grade of radiotherapy effect was determined based on the histopathological criteria of the Japanese Society for Esophageal Diseases. Grade 0 (•), ineffective; Grade 1 (○), slightly effective; Grade 2 (▴), moderately effective; and Grade 3 (▵), markedly effective. Group A included patients whose histological grade after radiotherapy was either 0 or 1, and group B included patients whose grade was either 2 or 3. The statistical analysis was performed using the Mann–Whitney U-test.